Cell-Penetrating Peptide Delivers Gene-Silencing Therapy to Leukemia Cells in the Lab
An endosomolytic cell-penetrating peptide (EB1) and PEG-decorated cationic liposomes both effectively delivered anti-BCR-ABL1 siRNA into chronic myeloid leukemia cells, with liposomes producing more effective gene silencing and growth arrest.
Quick Facts
What This Study Found
Both EB1 cell-penetrating peptide and PEG-cationic liposomes delivered anti-BCR-ABL1 siRNA into CML K562 cells, with liposomes producing more effective gene silencing and proliferation inhibition.
Key Numbers
siRNA targeting BCR-ABL1; CPP + cationic liposome delivery system; growth arrest demonstrated in CML cells in vitro.
How They Did This
In vitro study comparing EB1 peptide and 2X3-DOPE-DSPE-PEG2000 liposomes for siRNA delivery into K562 human CML cells. Gene expression and cell proliferation assessed.
Why This Research Matters
Drug resistance in CML is a serious clinical problem. Gene-silencing therapy targeting BCR-ABL1 could bypass resistance mechanisms entirely, and developing effective delivery systems is the key barrier to making this approach clinically viable.
The Bigger Picture
Cell-penetrating peptides are increasingly important as delivery vehicles for biologics that can't cross cell membranes on their own. While liposomes outperformed in this study, peptide-based delivery offers advantages in targeting and biodegradability that could be optimized for clinical use.
What This Study Doesn't Tell Us
In vitro study in a single CML cell line (K562). No in vivo testing. Liposomes outperformed peptide delivery for this application. Clinical translation requires animal studies for toxicity, distribution, and efficacy. Durability of gene silencing not assessed.
Questions This Raises
- ?Can EB1 peptide delivery be optimized to match liposome efficiency?
- ?Would combining peptide targeting with liposome delivery create a superior system?
- ?Can this siRNA approach overcome the specific mutations causing tyrosine kinase inhibitor resistance in CML?
Trust & Context
- Key Stat:
- Effective BCR-ABL1 silencing Both peptide and liposome delivery systems suppressed the leukemia-driving gene in CML cells
- Evidence Grade:
- Preliminary evidence — in vitro proof-of-concept in a single cell line. Demonstrates feasibility but requires significant preclinical development.
- Study Age:
- Published in 2024. Contributes to the growing field of peptide-mediated nucleic acid delivery for cancer therapy.
- Original Title:
- Cell-penetrating peptide and cationic liposomes mediated siRNA delivery to arrest growth of chronic myeloid leukemia cells in vitro.
- Published In:
- Biochimie, 221, 1-12 (2024)
- Authors:
- Vysochinskaya, Vera, Zabrodskaya, Yana, Dovbysh, Olesya, Emelyanov, Anton, Klimenko, Vladimir, Knyazev, Nikolay, Terterov, Ivan, Egorova, Marya, Bogdanov, Alexey, Maslov, Michael, Vasin, Andrey, Dubina, Michael
- Database ID:
- RPEP-09454
Evidence Hierarchy
Frequently Asked Questions
Can peptides help deliver gene therapy to cancer cells?
Yes — this study showed that a cell-penetrating peptide called EB1 can carry gene-silencing molecules (siRNA) into leukemia cells. The siRNA targets the specific gene that drives the cancer, potentially offering a way to treat leukemia that has become resistant to current drugs.
Why is it hard to get gene therapy into cells?
Cell membranes act as barriers that block most therapeutic molecules from entering. Cell-penetrating peptides can cross these barriers and carry cargo inside. In this study, both a peptide and tiny fat bubbles (liposomes) successfully delivered gene-silencing molecules into leukemia cells.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09454APA
Vysochinskaya, Vera; Zabrodskaya, Yana; Dovbysh, Olesya; Emelyanov, Anton; Klimenko, Vladimir; Knyazev, Nikolay; Terterov, Ivan; Egorova, Marya; Bogdanov, Alexey; Maslov, Michael; Vasin, Andrey; Dubina, Michael. (2024). Cell-penetrating peptide and cationic liposomes mediated siRNA delivery to arrest growth of chronic myeloid leukemia cells in vitro.. Biochimie, 221, 1-12. https://doi.org/10.1016/j.biochi.2024.01.006
MLA
Vysochinskaya, Vera, et al. "Cell-penetrating peptide and cationic liposomes mediated siRNA delivery to arrest growth of chronic myeloid leukemia cells in vitro.." Biochimie, 2024. https://doi.org/10.1016/j.biochi.2024.01.006
RethinkPeptides
RethinkPeptides Research Database. "Cell-penetrating peptide and cationic liposomes mediated siR..." RPEP-09454. Retrieved from https://rethinkpeptides.com/research/vysochinskaya-2024-cellpenetrating-peptide-and-cationic
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.